Hormonal
Administration of specific probiotic strains (e.g., Lactobacillus gasseri BNR17, L. acidophilus La5, Bifidobacterium lactis Bb12) and prebiotics (e.g., inulin-type fructans) reduces abdominal visceral fat, body weight, and fasting plasma glucose in overweight or obese individuals.
If you are overweight with visceral fat, adding specific probiotic strains (like L. gasseri or B. lactis) or prebiotics (like inulin) to your daily diet for at least 12 weeks can help reduce belly fat and improve blood sugar control. This works best when combined with a healthy diet, as the bacteria help regulate satiety hormones.
In the active FM group, abdominal visceral and subcutaneous fat areas significantly (P < 0.01) decreased from baseline by an average of 4.6 and 3.3%, respectively... Body weight and other measures also decreased significantly (P < 0.001) as follows: body weight, 1.4%; BMI, 1.5%; waist, 1.8%; and hip, 1.5%.
Why this rating
The paper reviews multiple randomized controlled trials (RCTs) in humans showing statistically significant improvements, though sample sizes vary.
Source
Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics
Mingqian He et al. · Cell & Bioscience · 2017
DOI 10.1186/s13578-017-0183-1
More from this paper
- Consumption of prebiotics (specifically inulin-type fructans) and probiotics reduces serum total and LDL cholesterol levels in hypercholesterolemic or dyslipidemic individuals.Good
- Administration of Akkermansia muciniphila improves glucose metabolism and reduces fasting hyperglycemia in type 2 diabetic mouse models by decreasing gluconeogenesis.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →